Contract research, development, and manufacturing organization Sai Life Sciences sees growing demand from Big Pharma clients diversifying away from China.
The 700,000-square-foot, multi-site project is part of the company’s broader effort to expand domestic production capacity and strengthen U.S. pharmaceutical supply chains.
The agreement focuses on integrating ambient temperature biosample preservation with advanced 3D organoid models to support preclinical research and biotech developers.
